LMAT logo

LEMAITRE VASCULAR INC

LMATNASDAQ
πŸ† #2048 by market capEarnings Oct 22US Equity
$551.53β–Ό $20.79 (βˆ’3.77%)
Simulated price
πŸ””
Track LMAT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.8%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.86B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+13.5%
Healthy
πŸ“ŠGross Margin
72.9%
High
πŸ’΅FCF Margin
28.1%
Strong
βš–οΈP/S Ratio
7.1x
Fair
Otter Score
68
Fair
No chart data available for LMAT.

Trading Snapshot

Day Range
$546.55 – $558.24
52-Week Range
$78.22 – $118.01
Volume
$1.79B
Avg Volume
$1.83B
Shares Outstanding
22.9M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$250M
Last Q Revenue
$70M
P/E Ratio
28.1
P/S Ratio
7.1x
EPS (TTM)
$2.87
Dividend Yield
1.17%
Dilution (1yr)
+0.3%

Why Investors Own LMAT

  • βœ“High-growth profile β€” revenue up +20.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 71% gross margin and 30% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LMAT logo

LEMAITRE VASCULAR INC

LMAT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$250Mβ–² +13.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
71.5%β–² +4.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$68Mβ–² +30.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$74Mβ–² +100.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
23.0Mβ–² +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$157Mβ–² +$3M YoY
StockOtter Β· stockotter.space

About LEMAITRE VASCULAR INC

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$728.38
β–² +32.1% Upside
High Target$791.64
Low Target$668.39
Based on 22 analysts

Latest News & Updates